Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D01RUN
|
||||
| Former ID |
DNC000014
|
||||
| Drug Name |
(R)-Rolipram
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [537166] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C16H21NO3
|
||||
| Canonical SMILES |
COC1=C(C=C(C=C1)C2CC(=O)NC2)OC3CCCC3
|
||||
| InChI |
1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)/t12-/m0/s1
|
||||
| InChIKey |
HJORMJIFDVBMOB-LBPRGKRZSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
7885372, 7885374, 10300167, 11111747, 11112814, 11113776, 11113777, 11113778, 12016200, 16133703, 36890033, 46392972, 46393090, 46507909, 46507984, 46508075, 50100342, 57404852, 76143228, 85789023, 87235809, 91746538, 93165425, 103332718, 103973669, 104224905, 104638908, 124881346, 124882649, 124882650, 124882651, 124882652, 126616648, 128070171, 134341264, 135266207, 135697605, 137009721, 142521916, 143494407, 144080082, 144220532, 152030706, 152164502, 152238532, 160779380, 160832182, 160965177, 162023069, 162183652
|
||||
| Target and Pathway | |||||
| Target(s) | CAMP-specific 3',5'-cyclic phosphodiesterase 4A | Target Info | Inhibitor | [537166] | |
| CAMP-specific 3',5'-cyclic phosphodiesterase 4B | Target Info | Inhibitor | [537166] | ||
| PDE4 | Target Info | Inhibitor | [535739], [537166] | ||
| NetPath Pathway | IL5 Signaling Pathway | ||||
| IL2 Signaling Pathway | |||||
| References | |||||
| Ref 535739 | Phosphodiesterase 4 in osteoblastic osteosarcoma cells as a potential target for growth inhibition. Anticancer Drugs. 2003 Jun;14(5):377-81. | ||||
| Ref 537166 | PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2009 Jun;296(6):L959-69. Epub 2009 Mar 20. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.